ArticleFrontiers in pharmacology2020

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points.

Jinmei Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.